Lantern Pharma Inc. (LTRN)
After hours:
| Previous close | 5.10 |
| Open | 5.29 |
| Bid | 5.22 x 100 |
| Ask | 5.48 x 100 |
| Day's range | 5.21 - 5.68 |
| 52-week range | 2.38 - 11.99 |
| Volume | |
| Avg. volume | 333,121 |
| Market cap | 57.896M |
| Beta (5Y monthly) | 1.40 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -1.47 |
| Earnings date | 07 May 2024 - 13 May 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 18.00 |
Business WireLantern Pharma Launches "Webinar Wednesdays" Featuring World-Class Physician Scientists & Key Opinion Leaders Discussing Critical Areas of Oncology Drug Development
DALLAS, April 24, 2024--Lantern Pharma Inc. (NASDAQ: LTRN), an artificial intelligence ("AI") company developing targeted and transformative cancer therapies using its proprietary RADR® AI and machine learning ("ML") platform with multiple clinical-stage drug programs, announced today that – the company has launched Webinar Wednesdays, a webinar series that focuses on areas of high oncology drug development interest with leading physicians, scientists and Lantern collaborators in drug developmen
Business WireLantern Pharma Receives Regulatory Approval to Expand Harmonic™ Clinical Trial for Non-Small Cell Lung Cancer in Never-Smokers into Japan and Taiwan
DALLAS, April 22, 2024--Lantern Pharma Inc. (NASDAQ: LTRN), an artificial intelligence ("AI") company developing targeted and transformative cancer therapies using its proprietary RADR® AI and machine learning ("ML") platform with multiple clinical-stage drug programs, announced today that – the company has received regulatory approval to expand its Harmonic™ trial, a Phase 2 clinical study evaluating LP-300 in non-small cell lung cancer (NSCLC) in never-smokers in both Japan and Taiwan. Approxi
Insider MonkeyLantern Pharma Inc. (NASDAQ:LTRN) Q4 2023 Earnings Call Transcript
Lantern Pharma Inc. (NASDAQ:LTRN) Q4 2023 Earnings Call Transcript March 18, 2024 Lantern Pharma Inc. isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Good afternoon, and welcome to our Fourth Quarter and Year End 2023 Earnings Call. As a reminder, […]
